glucocorticoid-free remission
J&J’s Tremfya Fails to Meet Primary Endpoint in Giant Cell Arteritis Trial
Tremfya, Johnson & Johnson, Giant Cell Arteritis, Phase II Trial, Primary Endpoint, Glucocorticoid-Free Remission
Actionable Insights Powered by AI
Tremfya, Johnson & Johnson, Giant Cell Arteritis, Phase II Trial, Primary Endpoint, Glucocorticoid-Free Remission